ClinicalTrials.gg
Not yet recruitingNCT07640906DOUBLE-ACEUpdated Jun 11, 2026

AI-Assisted Chest-CT Reporting for Enhanced Speed and Quality (The DOUBLE-ACE Study)

An observational study in Thoracic Diseases, Chest CT Scan and Artificial Intelligence (AI) in Diagnosis, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Shanghai Zhongshan Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn if an AI assistant tool can help doctors who read chest CT scans (called radiologists) write their reports faster and just as well or better. Chest CT scans are common pictures taken of the inside of the chest to help with diagnosis. The main questions the study aims to answer are: (1) Does using the AI tool save radiologists time when writing their reports? (2) Are the final reports written with the AI tool's help as good as or better than reports written without it? To answer these questions, researchers will compare two time periods at several hospitals. They will look at how long it took to write reports and how good the reports were, both from a time before the AI tool was available and from a time after it was in regular use. In this study, radiologists will use the AI tool as part of their normal daily work. The tool is built into the computer system they already use to look at scans. Researchers will then measure the time and quality of the reports produced during their regular shifts.

Read the detailed description

Here we provide a summary of the study's methodological framework, including a description of the AI system under evaluation, key quality control measures, and the data analysis plan. Comprehensive details regarding the full protocol, including eligibility criteria and outcome measures, can be found in the other modules of the study protocol.

  1. Background on the AI System: The study evaluates a clinically deployed AI-assisted reporting system, built upon an advanced multimodal foundation model trained on a large-scale chest CT dataset. Its performance, reliability, and generalizability have been established through rigorous validation on extensive internal and external datasets. Prior reader studies have demonstrated its clinical utility by significantly reducing reporting time through automated draft generation while maintaining or improving report quality, supporting its integration into real-world workflow for this evaluation.
  2. Quality Control: To ensure objective assessment, report quality will be scored by a panel of at least two independent, blinded thoracic radiologists using a standardized rubric, with inter-rater reliability calculated. A study-specific data dictionary and Standard Operating Procedures (SOPs) for data handling and analysis will be implemented to ensure reproducibility and auditability.
  3. Data Analysis Plan: A comparative statistical analysis between pre- and post-implementation groups is planned. Appropriate statistical tests (e.g., Mann-Whitney U test, mixed-effects models) will be applied based on data distribution and variable type. A sample size calculation will be conducted to ensure the study is adequately powered to detect a clinically meaningful difference in the primary efficiency endpoint. The primary analysis will be a paired comparison of outcomes (e.g., report time, quality) between the two phases for the participants who complete both. To address potential attrition (e.g., radiologist turnover during the study year) and the influence of radiologist experience, the analysis plan includes: (1) Accounting for and reporting any participant dropout between phases. (2) Conducting pre-specified subgroup or stratified analyses based on radiologist seniority (e.g., junior vs. senior) to examine its effect on the outcomes.
  4. Confounding Factor Control: To minimize potential bias, the study may identify collective variables (radiologists' sex, years of relevant professional experience, etc.) that may be considered potential confounding factors according to external experts' judgements. Certain patient-related information, such as diagnosis (infection, malignancy, cardiovascular disease, etc.) and clinical scenario (e.g., inpatient, outpatient, emergency), may also be collected retrospectively, where necessary, to evaluate model performance within specific diagnostic subgroups. The study will adopt multiple possible approaches for confounding factor adjustment or analysis, which may include stratified analyses and other related statistical methods.
  5. Potential Adjustments in Study Protocol or Analysis Methods: As the study may involve multiple centers, in case of ethical or administrative restrictions at certain time at specific sites, AI assistance may be temporarily suspended to approximate the scenario without AI assistance at those sites. In such cases, the corresponding results may be reported as the with-AI and without-AI phases, rather than labeling them as baseline and AI-available phases. Furthermore, radiologists who decline to provide demographic or occupational information (e.g., years of professional experience or sex)-variables that may serve as potential confounders-will be excluded from adjusted and stratified analyses that require such covariates. These approaches may need to be incorporated into confounding factor or stratified analyses, and we may update related conditions accordingly when necessary.
02

Conditions studied

  • Thoracic Diseases
  • Chest CT Scan
  • Artificial Intelligence (AI) in Diagnosis

Browse trials for

Keywords

  • Chest CT scan
  • artificial intelligence
03

In context

Thoracic Diseases

72 studies on the registry are indexed under Thoracic Diseases; 13 are open to participants now.

This study's planned enrollment of 75 is below the median of 122 across 19 observational studies indexed under Thoracic Diseases.

Browse Thoracic Diseases studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population is defined as follows:

  1. Radiologists: Attending radiologists who routinely interpret chest CT scans as part of their clinical duties at the participating medical centers.
  2. Chest CT Scans: Clinically indicated, non-contrast chest CT examinations acquired from the patient populations served by the participating centers. The scans are stratified into two groups based on the date of acquisition: before and after the implementation of the AI reporting system.

Eligibility criteria

The study participants include both the radiologists whose performance is evaluated and the chest CT scans they interpret. Eligibility criteria are defined for both.

1. Inclusion Criteria

1.1 For Radiologists

  1. Board-certified radiologists specializing in or routinely performing thoracic imaging.
  2. Employed at one of the participating study centers for the entire duration of both the without-AI and with-AI study periods.
  3. Interpreted a minimum of eligible chest CT scans (e.g., > 50 scans) during both the without-AI and with-AI data collection periods.

1.2 For Chest CT Scans

  1. Non-contrast chest CT examinations performed for any clinical indication.
  2. Scans completed and finalized during the defined with-AI or without-AI study periods.
  3. Patient age 18 years or older at the time of the scan.

2. Exclusion Criteria

2.1 For Radiologists:

  1. Radiologists who joined, left, or were on extended leave (e.g., >4 weeks) from the participating center between the with-AI and without-AI study periods.
  2. Radiologists who interpreted fewer than the minimum required number of eligible scans in either study period.
  3. Radiologists who voluntarily decline to have their de-identified performance data included in the study analysis.
  4. Radiologists who decline to provide demographic or occupational information (e.g., years of professional experience or sex)-variables that may serve as potential confounders-will be excluded from adjusted and stratified analyses that require such covariates.

2.2 For Chest CT Scans

  1. CT scans of pediatric patients (age \< 18 years).
  2. Contrast-enhanced chest CT studies.
  3. Studies performed for specific procedural guidance (e.g., , ablation).
  4. Studies deemed technically inadequate for primary interpretation by radiologist (e.g., severe motion artifact, incomplete study).
  5. Studies for which the AI system fails to generate a valid preliminary report draft. This includes possible system failures, algorithm errors, or cases where the generated draft is deemed technically unusable (e.g., empty, garbled, or based on critically flawed image analysis).
  6. The lack of relevant information (diagnosis, clinical scenario, etc.). Chest CT data will be excluded from corresponding analyses if the required information, which is necessary for confounding control, subgroup analyses, or other pre-specified analyses, is unavailable. Such scenarios include data that cannot be retrospectively retrieved, incompletely recorded, or restricted due to ethical or institutional requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Radiologists with/without chest CT interpretation AI assistant

    This study employs a single-arm, within-subjects design. A cohort of radiologists will be followed through two sequential practice phases: (1) Baseline (Control) Phase: Participants interpret and report on chest CT scans using their standard clinical workflow without AI assistance. (2) AI-available phase: The same participants interpret and report on a different set of chest CT scans with the integrated AI-assisted reporting system activated in their workflow.

    Device: An AI-assisted reporting system integrated into the clinical workflow, providing automated draft generation to assist with chest CT interpretation

Interventions

  • DeviceAn AI-assisted reporting system integrated into the clinical workflow, providing automated draft generation to assist with chest CT interpretation

    The intervention under evaluation is an AI-assisted diagnostic reporting system, integrated directly into the radiologists' workflow. The system analyzes the CT images in real time using an AI model and automatically generates a structured, preliminary radiology report draft. The interpreting radiologist reviews this AI-generated draft, which is presented within their familiar reporting interface. The radiologist then actively edits, confirms, supplements, or overrides the draft content as necessary before finalizing and signing the report. This intervention is distinguished from other AI tools by its focus on end-to-end reporting efficiency via integrated draft generation within the radiologist's classic workflow. It moves beyond simple abnormality detection or highlighting by generating a complete, structured narrative report draft, aiming to reduce dictation/typing time and minimize oversight of findings.

06

What researchers measure

Primary outcomes

  1. Change in Average Image Interpretation Time

    Comparison of the average time taken by participating radiologists to complete standard chest CT interpretation tasks, measured both with and without use of the automated interpretation tool. The time will be recorded from the start to the completion of each individual reading case.

    Time frame: Time of interpretation will be collected once the data become fully available (generally within 2 weeks after the planned primary completion date). Final aggregated analysis will be completed within 3 months after the collection of potential confounders.

  2. Change in Chest CT Report Quality Score

    Comparison of the subjective quality of chest CT reports written with and without automated tool support. Blinded external experts will evaluate the subjective quality of all sampled reports using a 10-point rating scale, with scores ranging from 1 (poorest quality) to 10 (highest quality).

    Time frame: Reports will be distributed to external experts for scoring once the data become available, with scoring results returned within 7 days. Final aggregated analysis will be completed within 3 months after the collection of potential confounders.

Other outcomes

  1. Radiologist Editing Intensity on AI-Generated Report Drafts

    This measure quantifies the extent of modification a radiologist makes to the initial draft report generated by the AI system. Editing intensity will be algorithmically calculated for each report in the with-AI period. A common method is the normalized edit distance (e.g., Levenshtein distance) or the percentage of text modified between the AI-generated draft and the radiologist's final signed report.

    Time frame: Report texts will be collected once the data become fully available (generally within 2 weeks after the planned primary completion date). Final aggregated analysis will be completed within 3 months after the collection of potential confounders.

07

Study locations

2 sites
08

References and documents

Publications

  • Teo ZL, Thirunavukarasu AJ, Elangovan K, Cheng H, Moova P, Soetikno B, Nielsen C, Pollreisz A, Ting DSJ, Morris RJT, Shah NH, Langlotz CP, Ting DSW. Generative artificial intelligence in medicine. Nat Med. 2025 Oct;31(10):3270-3282. doi: 10.1038/s41591-025-03983-2. Epub 2025 Oct 6. PubMed 41053447 ↗
  • Chen SF, Alyakin A, Seas A, Yang E, Choi JJ, Lee JV, Chen AL, Warman PI, Bitolas RT, Steele RJ, Alber DA, Oermann EK. LLM-assisted systematic review of large language models in clinical medicine. Nat Med. 2026 Mar;32(3):1152-1159. doi: 10.1038/s41591-026-04229-5. Epub 2026 Mar 3. PubMed 41776077 ↗

Individual participant data

Plan to share: No — This is an observational study analyzing aggregated, de-identified operational metrics (e.g., radiologist efficiency, report quality scores) derived from routine clinical practice. The data are not collected as part of a prospective clinical trial and are not structured for independent analysis. Findings will be disseminated through peer-reviewed publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Aug 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 11, 2026
StartEst.
Jun 2026
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640906
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jun 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Xiaodan Ye, MD, PhD
Contact
yuanyxd@163.com
+86-13761459998
Weiqiu Jin, MD
Contact
jinwqzsh@fudan.edu.cn
Mengsu Zeng, MD, PhD
study chair · Department of Radiology, Zhongshan Hospital, Fudan University
Dinggang Shen, PhD
study director · United Imaging Intelligence, Shanghai
Jianying Gu, MD, PhD
study director · Department of Radiology, Zhongshan Hospital, Fudan University
Dijia Wu, PhD
study director · United Imaging Intelligence, Shanghai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion